MEDAPIA

This brand name is authorized in Lithuania, Malta, Spain.

Active ingredients

The drug MEDAPIA contains one active pharmaceutical ingredient (API):

1	Entacapone UNII 4975G9NM6T - ENTACAPONE
	Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa.
	Read more about Entacapone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MEDAPIA Film-coated tablet	MPI, EU: SmPC	Medicines Authority (MT)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N04BX02	Entacapone	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BX Other dopaminergic agents
Discover more medicines within N04BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	82845
LT	Valstybinė vaistų kontrolės tarnyba	1084719, 1084720, 1084721, 1084722, 1084723, 1084724
MT	Medicines Authority	MA032/13201